Eckert & Ziegler BEBIG, Mick Radio-Nuclear Instruments, WOLF-Medizintechnik (WOmed)

Press Releases

We are keeping you informed! If you have questions regarding our press releases, feel free to contact us via the website´s contact form. Stay up-to-date with our companies latest news:
 
Print

Eckert & Ziegler BEBIG provides the first HDR brachytherapy afterloader for Barbados

Seneffe, Belgium, February 8, 2016, Eckert & Ziegler BEBIG is proud to announce that it has provided the first High Dose Rate (HDR) afterloader for Barbados which represents an important step in the country's fight against cancer. The first gynecological patient has already begun treatment with the SagiNova® device.

"We are very happy that the Queen Elizabeth Hospital in Bridgetown decided in favour of our SagiNova® HDR afterloader and therewith introduced the first and to date only brachytherapy system to Barbados." states Kentaro Mazur, Area General Manager for Eckert & Ziegler BEBIG in Latin America. He adds that the hospital was impressed by the safety features of the device and the broad HDR applicator portfolio together with Eckert & Ziegler BEBIG`s long record of experience in HDR brachytherapy.

SagiNova® will be used initially to treat cervical cancer which ranks as the 2nd most frequent cancer and also the 2nd leading cause of cancer deaths in women aged 15 to 44 years in Barbados. The Oncology Center of the Queen Elizabeth Hospital is expecting to carry out three to four treatments a day. Additionally, they plan to introduce SagiNova® for other brachytherapy treatments such as breast, prostate and esophagus.

About High Dose Rate (HDR) Brachytherapy
HDR brachytherapy allows radiation oncologists to deliver the radiation quickly, most often as an outpatient procedure. During this procedure a computer driven apparatus, called a remote afterloading device, pushes the radioactive source attached to a drive wire through transfer tubes and applicators to the treatment site. The radioactive source can be moved in millimeter increments and remain in a certain position (dwell position) for a predetermined amount of time to optimize the dose delivered. When the desired treatment dose has been achieved, the remote afterloading device automatically withdraws the radioactive source so there is no residual radiation or radioactivity.
HDR brachytherapy has been used since the 1960s and today is applied to treat cancers in body sites such as gynecological, rectal, prostate and breast. The procedure enables an accurate and precise tumor-specific radiation dose delivery in a shorter course of treatment compared to other types of radiation treatment modalities while preserving the structure and function of the organ(s) treated and nearby.

About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treat­ment of cancer using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 150 people. The company has been listed on the Euronext stock exchange since April 1997.

Contact:
Annica Witt
Marketing Communication Manager
marketing@bebig.com
www.bebig.com

Back